Anti-GATA3 gene therapy - sterna biologicals

Drug Profile

Anti-GATA3 gene therapy - sterna biologicals

Alternative Names: hgd40; SB 010; SB 011; SB 012

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sterna biologicals; University of Marburg
  • Developer German Center for Lung Research; sterna biologicals
  • Class Anti-inflammatories; Antiasthmatics; Catalytic DNA; Gene therapies; Skin disorder therapies
  • Mechanism of Action GATA3 transcription factor inhibitors; Gene transference; Interleukin 13 expression inhibitors; Interleukin 4 expression inhibitors; Interleukin 5 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Ulcerative colitis

Most Recent Events

  • 19 Feb 2018 Interim efficacy data from the phase IIa SECURE trial in Ulcerative colitis released by Sterna biologicals
  • 11 Sep 2017 sterna biologicals completes a phase II trial for Chronic obstructive pulmonary disease in Germany (Inhalation) (DRKS00006087)
  • 09 Sep 2017 Efficacy and adverse events data from a phase IIa trial in Chronic obstructive pulmonary disease presented at the at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top